Loading clinical trials...
Loading clinical trials...
A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
Conditions
Interventions
CSCJC3456 tablet
Locations
2
China
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
The First Hospital of China Medical University
Shenyang, Liaoning, China
Start Date
February 13, 2025
Primary Completion Date
June 30, 2027
Completion Date
June 30, 2028
Last Updated
February 2, 2026
NCT06658951
NCT07292402
NCT06912152
NCT07480733
NCT07363369
NCT06231550
Lead Sponsor
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions